The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head

Last updated: July 7, 2025
Sponsor: The Cleveland Clinic
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Musculoskeletal Diseases

Osteomyelitis

Bone Neoplasm

Treatment

Genex with ABMC

Clinical Study ID

NCT05706909
22-580
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject is at least 18 years or older with osteonecrosis of the femoral head

  • Surgeon considers the patient appropriate for the core decompression procedure ofthe hip

  • Subject provides voluntarily signature on the IRB approved Informed Consent Form

  • Subject must be physically and mentally willing and able, in the Investigator'sopinion at the time of enrollment, to be compliant with the protocol and completethe study protocol and follow ups

Exclusion

Exclusion Criteria:

  • Subject is pregnant at the time of surgery

  • Subject is incarcerated

  • Subject is not comfortable with speaking, reading and understanding questions andproviding responses in an available language for the questionnaires provided for thestudy

Study Design

Total Participants: 22
Treatment Group(s): 1
Primary Treatment: Genex with ABMC
Phase:
Study Start date:
February 08, 2023
Estimated Completion Date:
July 31, 2027

Study Description

Avascular necrosis (AVN) or osteonecrosis (ON) of the femoral head refers to a condition in bone metabolism when cells of the trabecular bone (porous bone found at the end of long bones like the femur) in the hip spontaneously die. Depending on the amount of femoral head involvement, parts of the surface, like the articular surface that do not have blood vessels may collapse as the disease advances. Although the exact common occurrence of AVN or ON is unknown, the incidence is estimated to be between 20,000 to 30,000 newly diagnosed patients each year in the US.

Core decompression of the hip is a minimally invasive surgical technique performed to manage symptoms in early stages (precollapse) of the condition. The procedure involves drilling holes into the femoral head to relieve pressure and create channels for new blood vessels to nourish the affected areas. Multiple adjuncts to core decompression, such as structural bone grafts, bone marrow concentrates, and bone proteins have been developed to accelerate the healing process in these patients. In recent years, considerable research activity has also been expanded to find new bone substitutes with osteoconductive properties (where bone grows on a surface) for the use in the treatment of surgically created defects.

Genex® Bone Graft Substitute is a catalyst for bone healing. It complements the body's natural healing processes and encourages normal bone structure to be restored at a steady rate. Over 12 months, the graft matrix is completely absorbed and replaced by bone. No foreign artifacts are left behind to impair structural integrity.

Connect with a study center

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.